d-Penicillamine2,5-enkephalin作为底物考察三明治大鼠原代肝细胞的转运体功能研究

中国临床药理学与治疗学 ›› 2013, Vol. 18 ›› Issue (5): 506-512.

d-Penicillamine2,5-enkephalin作为底物考察三明治大鼠原代肝细胞的转运体功能研究

郭岑¹, 赫蕾¹, 姚丹², 潘国宇², 王广基¹

¹中国药科大学药物代谢动力学重点实验室,南京 210009,江苏;
²中国科学院上海药物研究所药物安全评价研究中心,上海 201203

收稿日期:2013-02-25 修回日期:2013-04-20 出版日期:2013-05-26 发布日期:2013-05-22
通讯作者: 潘国宇,男,教授,硕导,研究方向:药物代谢动力学及药物安全性评价。Tel: 021-20231000-4023 E-mail: gypan@mail.shcnc.ac.cn王广基,男,教授,博导,研究方向:药物代谢动力学。Tel: 025-83271128 E-mail: guangjiwang@hotmail.com
作者简介:郭岑,女,硕士研究生,研究方向:药物代谢动力学。Tel: 13761075495 E-mail: carolguo2010@hotmail.com
基金资助:
国家自然科学基金项目(81173116);江苏省药代动力学重点实验室提升项目(BM20120102)

Application of d-Penicillamine2,5-enkephalin to characterization of sandwich-cultured hepatocytes transport activities

GUO Cen¹, HE Lei¹, YAO Dan², PAN Guo-yu², WANG Guang-ji¹

¹Key Laborary of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing 210009, Jiangsu, China;
²Center for Drug Safety Evaluation & Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China

Received:2013-02-25 Revised:2013-04-20 Online:2013-05-26 Published:2013-05-22

摘要/Abstract

摘要： 目的: 通过液相色谱-串联质谱(LC/MS/MS)法测定d-Penicillamine2,5-enkephalin (DPDPE)在肝细胞和Hank's缓冲液中的浓度,研究DPDPE作为底物用于“三明治”培养大鼠原代肝细胞(SCRH)的转运体功能。方法: 将SCRH与溶于Hank's缓冲液的DPDPE共温孵,采用LC/MS/MS法测定细胞内蓄积的和外排到缓冲液中的DPDPE浓度,用于评价模型药物α-萘异硫氰酸酯(ANIT)对参与DPDPE摄取的Oatp和负责DPDPE外排的Mrp2的转运功能的影响。结果: 建立的样品处理和测定方法能够满足体外转运实验需要的灵敏度和线性范围,在Hank's缓冲液中线性范围为0.5~50 ng/mL(r²=0.9995),在细胞基质中线性范围为 0.1~5 ng/well(r²=0.9997),样品处理操作简便。日内日间精密度(RSD)均小于15%;提取回收率大于65%。ANIT可抑制DPDPE在SCRH胆管侧的外排及基底侧的摄取,对基底侧外排无显著影响。结论: 该分析方法选择性好,灵敏度高,操作简便,并成功地用于将DPDPE作为探针底物研究SCRH模型上转运体的功能。

关键词: 转运体, “三明治”培养大鼠原代肝细胞, LC/MS/MS, DPDPE

Abstract: AIM: To develop a sensitive and rapid method for determining the concentration of d-Penicillamine2,5-enkephalin (DPDPE) in hepatocytes and Hank's buffer by LC/MS/MS. And to evaluate the function of transporters in sandwich-cultured rat hepatocytes (SCRH) using DPDPE as the probe substrate.METHODS: Co-incubate DPDPE with SCRH treated by alpha-naphthylisothiocyanate, the model compound, and measure the accumulation and the efflux of DPDPE by SCRH. The concentration of DPDPE in hepatocytes or Hank's buffer was determined by LC/MS/MS.RESULTS: DPDPE had a good linearity from 0.5 to 50 ng/mL (r²=0.9995) in Hank's buffer and from 0.1 to 5 ng/well (r²=0.9997) in hepatocytes in the LC/MS/MS method established in this study. This method was sensitive enough to quantify DPDPE used as probe substrate in SCRH transport studies. The inter- and intra-day precision (RSD) were less than 15% and the recoveries were above 65%. The basolateral uptake and canalicular efflux of DPDPE by SCRH was inhibited by ANIT without change in the basolateral efflux.CONCLUSION: The analytical method established here is selective, sensitive and feasible to determine DPDPE used as probe substrate in the evaluation of membrane transporters in SCRH.

Key words: Transporter, Sandwich-cultured rat hepatocytes, LC/MS/MS, DPDPE

中图分类号:

R969.1

郭岑, 赫蕾, 姚丹, 潘国宇, 王广基. d-Penicillamine2,5-enkephalin作为底物考察三明治大鼠原代肝细胞的转运体功能研究[J]. 中国临床药理学与治疗学, 2013, 18(5): 506-512.

GUO Cen, HE Lei, YAO Dan, PAN Guo-yu, WANG Guang-ji. Application of d-Penicillamine2,5-enkephalin to characterization of sandwich-cultured hepatocytes transport activities[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(5): 506-512.

参考文献

[1] Jedlitschky G, Hoffmann U, Kroemer HK. Structure and function of the MRP2 (ABCC2) protein and its role in drug disposition [J]. Expert Opin Drug Metab Toxicol, 2006, 2(3): 351-366.
[2] Boaglio AC, Zucchetti AE, Sanchez Pozzi EJ, et al. Phosphoinositide 3-kinase/protein kinase B signaling pathway is involved in estradiol 17β-D-glucuronide-induced cholestasis: complementarity with classical protein kinase C [J]. Hepatology, 2010, 52(4): 1465-1476.
[3] Lau YY, Wu CY, Okochi H, et al. Ex situ inhibition of hepatic uptake and efflux significantly changes metabolism: hepatic enzyme-transporter interplay [J]. J Pharmacol Exp Ther, 2004, 308(3): p. 1040-1045.
[4] 彭夏, 夏春华, 熊玉卿, 等. 有机阴离子转运多肽1A2对药物转运的影响[J]. 中国临床药理学与治疗学, 2010,15(4): 464-470.
[5] 李丹, 韩永龙, 余涛, 等. 体外肝代谢模型的优缺点及其应用[J]. 中国临床药理学与治疗学, 2011, 16(6): 688-694.
[6] Hartman JC, Brouwer K, Mandagere A, et al. Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes [J]. Can J Physiol Pharmacol, 2010, 88(6): 682-691.
[7] Gao B, Hagenbuch B, Kullak-Ublick GA, et al. Organic anion-transporting polypeptides mediate transport of opioid peptides across blood-brain barrier [J]. J Pharmacol Exp Ther, 2000,294(1): 73-79.
[8] Weber SJ, Greene DL, Sharma SD, et al. Distribution and analgesia of [3H] [D-Pen2, D-Pen5] enkephalin and two halogenated analogs after intravenous administration [J]. J Pharmacol Exp Ther, 1991, 259(3): 1109-1117.
[9] Chen C, Pollack GM. Extensive biliary excretion of the model opioid peptide [D-PEN2,5] enkephalin in rats [J]. Pharm Res, 1997, 14(3): 345-350.
[10] Hoffmaster KA, Zamek-Gliszczynski MJ, Pollack GM, et al. Multiple transport systems mediate the hepatic uptake and biliary excretion of the metabolically stable opioid peptide [D-penicillamine2,5] enkephalin [J]. Drug Metab Dispos, 2005, 33(2): 287-293.
[11] Hoffmaster KA, Zamek-Gliszczynski MJ, Pollack GM, et al. Hepatobiliary disposition of the metabolically stable opioid peptide [D-Pen2, D-Pen5] -enkephalin (DPDPE): pharmacokinetic consequences of the interplay between multiple transport systems [J]. J Pharmacol Exp Ther, 2004, 311(3): 1203-1210.
[12] Kotani N, Maeda K, Watanabe T, et al. Culture period-dependent changes in the uptake of transporter substrates in sandwich-cultured rat and human hepatocytes [J]. Drug Metab Dispos, 2011, 39(9): 1503-1510.
[13] Liu X, LeCluyse EL, Brouwer KR, et al. Biliary excretion in primary rat hepatocytes cultured in a collagen-sandwich configuration [J]. Am J Physiol, 1999, 277(1 Pt 1): G12-21.
[14] Liu X, LeCluyse EL, Brouwer KR, et al. Use of Ca²⁺ modulation to evaluate biliary excretion in sandwich-cultured rat hepatocytes [J]. J Pharmacol Exp Ther, 1999, 289(3): 1592-1599.

[1]	郝潇, 赵美, 王文静, 张飞飞, 刘惠良, 党懿, 李树仁, 齐晓勇. 钠-葡萄糖共转运体2抑制剂在急性心肌梗死应用研究进展[J]. 中国临床药理学与治疗学, 2023, 28(7): 824-831.
[2]	何雪茹, 李颖, 马银玲, 付裕豪, 荀雪姣, 董占军. 索拉非尼和达格列净在大鼠体中药代动力学相互作用研究[J]. 中国临床药理学与治疗学, 2023, 28(5): 498-507.
[3]	潘淑, 吴义金, 张洒洒, 王启海, 罗婷婷, 殷勤. 基于OAT3介导的MTX治疗佐剂诱导性关节炎大鼠的药动学研究[J]. 中国临床药理学与治疗学, 2022, 27(5): 516-525.
[4]	陈佳音, 王丽, 王立军, 童刚领, 马洁, 陈西敬, 卢杨. 有机阳离子转运体基因多态性与奥沙利铂毒性及疗效的相关性研究[J]. 中国临床药理学与治疗学, 2022, 27(2): 171-177.
[5]	刘璐, 陈笑艳. 国产小分子化学创新药临床药物相互作用研究现状[J]. 中国临床药理学与治疗学, 2021, 26(8): 863-875.
[6]	孟强, 刘克辛. 转运体介导药物相互作用的研究现状及展望[J]. 中国临床药理学与治疗学, 2021, 26(8): 876-888.
[7]	周晗, 刘晓东. 生理药代动力学模型在创新药物评价中应用及其若干问题的思考[J]. 中国临床药理学与治疗学, 2021, 26(8): 889-913.
[8]	张远金, 黄盛博, 刘洁, 王昕. 药物代谢创新模型：基因编辑大鼠和小肠3D类器官[J]. 中国临床药理学与治疗学, 2021, 26(8): 914-922.
[9]	鲁琼, 朱海宏, 戚听听, 李国华, 滕欣琪, 屈强, 屈健. OCTN2基因多态性影响结直肠癌奥沙利铂化疗敏感性[J]. 中国临床药理学与治疗学, 2021, 26(4): 401-407.
[10]	钟凯龙, 王永胜, 陈方, 叶岩荣. 基于血脑屏障转运体的中枢神经系统疾病治疗策略探讨与展望#br#[J]. 中国临床药理学与治疗学, 2020, 25(8): 953-960.
[11]	李丹云, 牛培广, 史道华 . 基于谷氨酰胺代谢抗肿瘤药物的研究进展[J]. 中国临床药理学与治疗学, 2020, 25(7): 810-816.
[12]	沙碧君，周素凤，王璐，赵玉清，陈西敬，邵凤. 药物相互作用临床研究方法及进展[J]. 中国临床药理学与治疗学, 2019, 24(9): 1037-1045.
[13]	林敏，沈仲夏，钱敏才，崔力军，任列，蔡敏，沈鑫华. 5-羟色胺转运体基因多态性与抗抑郁剂治疗广泛性焦虑障碍疗效的关联[J]. 中国临床药理学与治疗学, 2019, 24(8): 903-909.
[14]	陈泓竹，刘建明，周芳，贾元威，王广基，张经纬. 内源性物质代谢对药物代谢处置的影响及机制研究[J]. 中国临床药理学与治疗学, 2019, 24(5): 580-588.
[15]	单晓蕾，付淑军，高广花，孙涛，王庆利，余珊珊. 基于代谢酶和转运体的体外药物相互作用研究概述与案例分析[J]. 中国临床药理学与治疗学, 2019, 24(10): 1165-1171.